Analyst Expectations for DICE Therapeutics's Future
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 7 analysts have published their opinion on DICE Therapeutics (NASDAQ:DICE) stock, with 3 bullish and 4 indifferent ratings. The average 12-month price target is $52.71, a 5.32% decrease from the previous average of $55.67.
June 20, 2023 | 8:02 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
DICE Therapeutics has received mixed opinions from 7 analysts, with an average 12-month price target of $52.71, representing a 5.32% decrease from the previous target.
The article provides an overview of analyst opinions on DICE Therapeutics stock, with 3 bullish and 4 indifferent ratings. The average 12-month price target has decreased by 5.32% from the previous target, indicating a potential short-term neutral impact on the stock price. The relevance, importance, and confidence scores are high due to the direct mention of DICE and the focus on analyst opinions.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100